Volume 272, Number 37,
Issue of September 12, 1997
pp. 23094-23103
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.
The Phosphatidyl-myo-inositol Anchor of the
Lipoarabinomannans from Mycobacterium bovis Bacillus
Calmette Guérin
HETEROGENEITY, STRUCTURE, AND ROLE IN THE REGULATION OF CYTOKINE
SECRETION*
(Received for publication, May 29, 1997, and in revised form, June 30, 1997)
Jérôme
Nigou
,
Martine
Gilleron
,
Bertrand
Cahuzac
,
Jean-Dominique
Bounéry
,
Manfred
Herold
§,
Martin
Thurnher
¶ and
Germain
Puzo

From the
Institut de Pharmacologie et de Biologie
Structurale du Centre National de la Recherche Scientifique, 118 route
de Narbonne, 31062 Toulouse Cedex, France, the ¶ Department of
Urology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck,
Austria, and the § Department of Internal Medicine,
University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
Lipoarabinomannans are major mycobacterial
antigens capable of modulating the host immune response; however, the
molecular basis underlying the diversity of their immunological
properties remain an open question. In this study a new extraction and
purification approach was successfully applied to isolate ManLAMs
(lipoarabinomannans with mannosyl extensions) from bacillus Calmette
Guérin leading to the obtention of two types of ManLAMs namely
parietal and cellular. Structurally, they were found to differ by the
percentage of mannooligosaccharide caps, 76 and 48%, respectively, and
also, thanks to a new analytical method, by the structure of the
phosphatidyl-myo-inositol anchor lipid moiety. A novel
fatty acid in the mycobacterium genus assigned to a
12-O-(methoxypropanoyl)-12-hydroxystearic acid
was the only fatty acid esterifying C-1 of the glycerol residue of the
parietal ManLAMs, while the phosphatidyl unit of the cellular ManLAMs
showed a large heterogeneity due to a combination of palmitic and
tuberculostearic acid. Finally, parietal and cellular ManLAMs were
found to differentially affect interleukin-8 and tumor necrosis
factor-
secretion from human dendritic cells. We show that parietal
but not cellular ManLAMs were able to stimulate tumor necrosis
factor-
secretion from dendritic cells. From these studies we
propose that the
1-[12-O-(methoxypropanoyl)-12-hydroxystearoyl]-sn-glycerol part is the major cytokine-regulating component of the ManLAMs. It
seems likely that modification of the ManLAM lipid part, which may
occur in hostile environments, could regulate macrophagic mycobacterial survival by altering cytokine stimulation.
INTRODUCTION
Tuberculosis remains the leading cause of human death among the
infectious diseases with over 3 million deaths each year (1). The
decline in tuberculosis in the developed countries has been reversed by
the tuberculosis cases arising in AIDS patients, among the homeless,
and by the emergence of Mycobacterium tuberculosis strains
resistant to the first-line drugs, which are isoniazid and ethambutol.
Also, from different trials, the efficiency of BCG1 vaccine to prevent
tuberculosis was found to range from 0 to 80% (2, 3).
Virulent mycobacteria survive and multiply within phagosomes of
mononuclear phagocytes. Despite conflicting results, there is a
consensus that phagosomes containing M. tuberculosis do not fuse with lysosomes and resist acidification (4). This survival can
also be correlated with the macrophage bactericide activity, which
appears to be modulated by mycobacterial cell wall components (5,
6).
From a molecular point of view, cell wall lipoarabinomannans (LAMs) are
clearly demonstrated to be pivotal mycobacterial antigens. They
regulate TNF-
production by phagocyte (5) and block the transcriptional activation of INF-
(6), thereby influencing the
intramacrophagic survival of mycobacteria. For instance, LAMs (PI-GAMs)
from Mycobacterium smegmatis, a fast growing mycobacterium that does not survive inside the macrophages, were found to stimulate phagocyte TNF-
production (7), whereas LAMs (ManLAMs) from the
pathogenic M. tuberculosis Erdman strain, which survives in the macrophages, have much a lower stimulatory activity (5). ManLAMs
were found to be endowed with other immunological activities. They
selectively bind murine and human phagocytes via the mannose receptor
and mediate the adhesion of pathogenic M. tuberculosis strains to this receptor (8, 9). In addition, ManLAMs from Mycobacterium leprae and M. tuberculosis
Erdman strains were found to be presented in the context of CD1
molecules and stimulate CD4/CD8 double negative 
T cells (10).
There is a general consensus that the ManLAMs isolated from BCG (11),
M. tuberculosis (12, 13), and M. leprae (14) share the same basic structure characterized by the following features:
a phosphatidyl-myo-inositol anchor, a mannan core, an arabinan domain, and mannooligosaccharide caps. Nevertheless, ManLAMs
from M. leprae and M. tuberculosis were found
to stimulate T cell clones with different fine specificities (10). This
phenomenon remains unclear, even if it was claimed that it arises from
the mannooligosaccharide caps frequency (10). This paradoxical
situation can be tentatively explained by the fact that structural and
functional ManLAMs studies were conducted on complex mixtures. This was
revealed by matrix-assisted laser desorption/ionization mass
spectrometry studies establishing an average ManLAM molecular mass of
17 kDa and giving a molecular heterogeneity estimated at 6 kDa (11). Moreover the structural analysis of the ManLAMs from
Mycobacterium bovis BCG revealed that around 50% of the
mannan cores were devoid of the expected
phosphatidyl-myo-inositol anchor, suggesting that the
analyzed fraction, containing arabinose and mannose, was a mixture of
lipoglycans and glycans (15).
We report here a new strategy to extract ManLAMs from M. bovis BCG, which can be extended to the LAMs from other
mycobacterial strains. The protocol enables the isolation of two types
of ManLAMs, namely parietal and cellular (16). In addition, a new
purification method was successfully developed allowing the separation
of glycans from lipoglycans. We demonstrate that cellular and parietal
ManLAMs differ by their PI anchor structure and by the frequency of the mannooligosaccharide caps. Drastic differences were also observed in
their capacity to stimulate cytokine secretion from human dendritic cells (DCs).
MATERIALS AND METHODS
ManLAMs Extraction and Purification
As explained in Fig. 1,
M. bovis BCG Pasteur strain cells were delipidated using
CHCl3/CH3OH, 1:1, v/v. The delipidated
mycobacteria were extracted six times by refluxing in 50% ethanol at
65 °C for 8 h. The resulting cells were washed and
disintegrated in ice by sonication (20 kHz, 600 watts, 15 min) and
using a French pressure cell (one step of lysis at a pressure
maintained above 200 megapascals). The ethanol/water extracts (parietal
fraction) were dried, incubated in 2% Triton X-100 (Sigma), and
dialyzed against it to eliminate most of the hydrophobic molecules such as phosphatidyl-myo-inositol mannosides. Triton X-100 was
removed by a partition
CHCl3/CH3OH/H2O, 2:1:1, v/v/v. The
water-soluble fraction containing lipoglycans, glycans, and proteins
was treated with both enzymes, trypsin (from bovine pancreas, Sigma)
and
-amylase (from Bacillus amyloliquefaciens, Boehringer
Mannheim GmbH), and dialyzed against water. Most of the proteins of the
cellular fraction were removed by a hot 80% (w/w) aqueous phenol
biphasic wash at 70 °C for 1 h. After enzymatic treatments by
trypsin,
-amylase, RNase A (from bovine pancreas, Sigma), and DNase
I (from bovine pancreas, Fluka), a step of dialysis removed the amino
acids, glucose, nucleotides, and phenol from the cellular glycans and lipoglycans. Triton X-114 phase separation technique was applied on
glycan and lipoglycan mixtures (see below). ManLAMs and LMs were then
separated by gel filtration. Sample (60 mg) was dissolved in 0.2 M NaCl, 0.25% sodium deoxycholate (w/v), 1 mM
EDTA and 10 mM Tris, pH = 8, to a final concentration
of 200 mg/ml, incubated 2 days at room temperature, and loaded on a gel
permeation Bio-Gel P-100 column (52 × 3 cm) eluted with the same
buffer at a flow rate of 5 ml/h. SDS-PAGE was performed as described by
Venisse et al. (11).
Fig. 1.
Purification scheme for the parietal and
cellular ManLAMs and related compounds from M. bovis BCG
Pasteur strain.
[View Larger Version of this Image (23K GIF file)]
Triton X-114 Phase Separation Method
As described by
Bordier (17), three precondensations of commercial Triton X-114 (Sigma)
were performed leading to a concentration of Triton X-114 in the
detergent-rich phase of 13.2% (w/v), corresponding to the stock
solution. The ManLAM containing fractions were dissolved in water (1 mg/ml final volume), and Triton X-114 stock solution was added to a
final concentration of Triton X-114 of 2% (w/v). The mixture was
homogenized at 4 °C for 1 h and then incubated at 37 °C to
allow separation into the detergent-rich and the detergent-depleted phases, the latter being collected. To optimize the fractionation between the glycans and the lipoglycans, these two phases were again
homogenized by adding either water or Triton X-114 stock solution to a
final Triton concentration of 2% and again separated. This process was
repeated twice leading to four detergent-rich and four
detergent-depleted phases, which were respectively pooled. From both
phases, the Triton X-114 was mainly removed by extraction with
CHCl3 (controlled by UV (17)), the resulting aqueous phases were dried and addition of absolute ethanol led to the precipitation of
lipoglycans and glycans.
Chemical Analysis
Carbohydrates and inositol were analyzed
as their trimethylsilyl glycosides dissolved in cyclohexane after
hydrolysis with 0.6 N HCl, 110 °C, 1 h.
Glycosyl linkage composition was analyzed after methylation of
polysaccharides according to the modified procedure from Ciucanu and
Kerek (18). The methylated polysaccharides were hydrolyzed with 2 N trifluoroacetic acid at 110 °C for 2 h, reduced
with NaBD4 10 mg/ml in NH4OH 1 M/C2H5OH, 1:1, v/v, freshly
prepared and peracetylated with acetic anhydride 1 h at 110 °C.
The alditol acetates were solubilized in cyclohexane before injection
in gas chromatography (GC) and gas chromatography coupled to mass
spectrometry (GC/MS).
Fatty acids were analyzed as their methyl esters. ManLAMs were
deacylated in 1 N NaOH, 37 °C, 2 h, and then
neutralized with HCl. Fatty acids were extracted using
cyclohexane/water, 1:1, v/v, and after drying under N2,
were methylated with 10% (w/w) BF3 in methanol (Fluka) at
60 °C for 5 min. Reaction was stopped by addition of water, and
fatty acid methyl esters were extracted as described above before
injection in GC and GC/MS. Pentadecanoic acid was used as internal
standard. Phosphorus was measured for the determination of the molar
ratio of fatty acids to phosphorus by the procedure described by
Schnitger et al. (19).
Acetolysis Procedure
3 mg of ManLAMs were treated with 400 µl of anhydrous acetic acid/acetic anhydride, 3:2, v/v, at 110 °C
for 12 h (20). The reaction mixture was dried and vortexed with
400 µl of cyclohexane/water, 1:1, v/v. The cyclohexane phase was
analyzed by GC/MS.
GC and GC/MS Analysis
GC was performed on a Girdel series
30 equipped with an OV1 capillary column (0.22 mm × 25 m)
using helium gas with a flow rate of 2.5 ml/min with a flame ionization
detector at 310 °C. The injector temperature was 260 °C, and the
temperature separation program was from 100 to 290 °C at a speed of
3 °C/min. GC/MS analysis were performed on a Hewlett-Packard 5889 X
mass spectrometer (electron energy, 70 eV) working on both electron
impact (EI) and chemical ionization modes using NH3 as
reagent gas (CI/NH3), coupled with a Hewlett-Packard 5890 gas chromatograph series II fitted with a similar OV1 column (0.30 mm × 12 m). Acetolysis products were analyzed on a 0.35-m
length column using a temperature separation program from 160 to
300 °C at a speed of 8 °C/min. The injector and interface
temperatures were 290 °C.
Capillary Electrophoresis
Analyses were performed on a
P/ACE capillary electrophoresis system (Beckman Instruments, Inc.) with
the cathode on the injection side and the anode on the detection
side. The electropherograms were acquired and stored on a Dell XPS P60
computer using the System Gold software package (Beckman Instruments,
Inc.).
2 µg of dried mild hydrolyzed (0.1 N HCl at 110 °C for
30 min) ManLAMs were mixed with 0.5 µl of 0.2 M
1-aminopyrene-3,6,8-trisulfonate (APTS) (eCAP N-Linked
oligosaccharides profiling kit, Beckman Instruments, Inc.) in 15%
acetic acid and 0.5 µl of a 1 M sodium cyanoborohydride
solution dissolved in tetrahydrofuran (Aldrich) (21). The reaction was
performed 90 min at 55 °C, and the samples were then diluted in 9 µl of water before injection. APTS derivatives were loaded by
applying 0.5 p.s.i. (3.45 kPa) vacuum for 5 s. Separations
were performed using a coated capillary column (eCAP N-CHO coated
capillary from eCAP N-Linked oligosaccharides profiling kit,
Beckman Instruments, Inc.) of 50 µm internal diameter with 40 cm
effective length (47 cm total length). Analyses were carried out at a
temperature of 20 °C with an applied voltage of 24 kV and using
degassed carbohydrate separation gel buffer (eCAP N-Linked oligosaccharides profiling kit, Beckman Instruments, Inc.) as running
electrolyte. Detection system consisted in a Beckman laser-induced fluorescence equipped with a 4-milliwatt argon-ion laser with the
excitation wavelength of 488 nm and emission wavelength filter of 520 nm.
NMR Spectroscopy
NMR spectra were recorded on a Bruker
AMX-500 spectrometer equipped with an Aspect X32 computer. Samples were
exchanged in D2O (Spin et Techniques, Paris, 99.9% purity)
with intermediate lyophilization, then dissolved in 99.96 atom % D2O and analyzed in 200 × 5-mm 535-PP NMR tubes. The
concentration of the NMR samples were 40 mg/ml for parietal ManLAMs and
120 mg/ml for cellular ManLAMs. Spectra were recorded at 313 K. The
1H NMR chemical shifts were referenced relative to internal
acetone signal at 2.225 ppm.
The one-dimensional phosphorus (31P) spectra were measured
at 202.46 MHz by employing a spectral width of 25 kHz, and phosphoric acid (85%) was used as the external standard (
P 0.0).
The data were collected in 32,768 complex data sets, and an exponential transformation (LB = 5 Hz) was applied prior the processing to 65,536 real points in the frequency domain. The spectrum was recorded with 64 scans for parietal ManLAMs and 512 scans for cellular ManLAMs.
The two-dimensional 1H-31P HMQC-HOHAHA spectra
were recorded without sample spinning in the proton-detected mode with
a Bruker 5-mm 1H broad band tunable probe with reversal
geometry using the Lerner and Bax pulse sequence (22). The GARP
sequence (23) at the carbon frequency was used as a composite pulse
decoupling during acquisition. Data were acquired in the
phase-sensitive mode using the time-proportional phase increment method
(24). For parietal ManLAMs, spectral widths of 607.38 Hz in
31P and 5005 Hz in 1H dimensions were used to
collect a 4096 × 42 (time-proportional phase increment) point
data matrix with 108 scans/t1 value expanded to
4096 × 1024 by zero filling. The mixing time was 34 ms. For parietal deacylated ManLAMs, spectral widths of 10 123 Hz in
31P and 4003 Hz in 1H dimensions were used to
collect a 4096 × 128 (time-proportional phase increment) point
data matrix with 96 scans/t1 value expanded to
4096 × 1024 by zero filling. The mixing time was 63 ms. In both
case, the relaxation delay was 1 s, and a sine bell window shifted
by
/2 was applied in both dimensions.
Cell Culture Media and Cytokines
The medium used in this
study was RPMI 1640 with 1% heat-inactivated (30 min, 56 °C) pooled
human AB serum, 50 units/ml penicillin, 50 µg/ml streptomycin, 2.5 µg/ml fungizone, 2 mM L-glutamine, 10 mM Hepes, 0.1 mM non-essential amino acids, 1 mM pyruvate, and 5 × 10
5 M
2-mercaptoethanol (all from Boehringer Ingelheim Bioproducts, Vienna,
Austria). Human albumin (for intravenous use; Octopharma, Vienna,
Austria) was added to a final concentration of 2 mg/ml (=complete
medium). Recombinant GM-CSF (Leucomax; 1.11 × 107
units/mg) was from Sandoz (Basel, Switzerland). Recombinant human IL-4
(2 × 107 units/mg) was kindly supplied by the
Schering-Plough Research Institute (Kenilworth, NJ).
DCs and Quantitation of Cytokines
Cultures of human DCs
were established as described (25). Briefly, mononuclear cells were
obtained by standard density gradient centrifugation on Ficoll-Paque
(Pharmacia Biotech Inc., Uppsala, Sweden). The adherent fraction (45 min, 37 °C) was cultured in complete medium containing 1000 units/ml
each GM-CSF and IL-4. Every other day, one-third of the medium was
replaced by fresh medium containing GM-CSF/IL-4. DCs were routinely
used at day 6. After extensive washing, the cells were recultured at
105 cells/ml with or without ManLAMs at the indicated
concentrations. Supernatants were harvested for IL-8 and TNF-
assays
after 6 h. The enzyme-linked immunosorbent assay was carried out
with a commercially available kit from CLB (Amsterdam, The Netherlands) specific for IL-8 and TNF-
. Cytokines were quantitated using a
microtiter plate reader.
RESULTS
Extraction and Purification of ManLAMs
The presence of ManLAMs, namely parietal ManLAMs, in ethanol/water
extracts from delipidated BCG Pasteur strain cells was unambiguously
established by routine carbohydrate analysis revealing the occurrence
of arabinose and mannose. This assumption was also supported by
SDS-PAGE analysis showing a characteristic broad band at 30 kDa. As
outlined in the purification scheme (Fig.
1), the resulting cells were disrupted
and extracted again by an ethanol/water mixture. This extract, analyzed
as mentioned above for the parietal extract, was found again to contain
ManLAMs: namely cellular ManLAMs (16).
The fraction containing parietal ManLAMs was submitted to the following
process: i) incubation in 2% Triton X-100 and dialysis against it to
remove the phosphatidyl-myo-inositol mannosides, ii)
elimination of the Triton X-100 by partition, iii) enzymatic hydrolysis
by trypsin and
-amylase to remove the protein and glucan
contaminants. At the end of this process, the parietal ManLAM fraction
was still contaminated by amphipathic glycoconjugates like LMs and the
expected glycans such as arabinomannans (AMs) and mannans.
Besides the different contaminants (proteins, glucans) described above
for the parietal ManLAM fraction, DNA and RNA were also present in the
cellular ManLAM fraction. All these contaminants were enzymatically
removed. To eliminate the glycans from the parietal and cellular ManLAM
fractions, the Triton X-114 phase separation method, which is
summarized below, was successfully applied.
Triton X-114 forms a clear micellar solution at 4 °C and two phases
at 22 °C, a hydrophilic detergent-depleted phase and an amphipathic
detergent-rich phase. The ManLAM fractions were dissolved in water (1 mg/ml final volume) and then preconditioned Triton X-114 stock solution
(17) was added to a final concentration of 2% Triton X-114 (w/v). The
mixture was homogenized at 4 °C for 1 h, then incubated at
37 °C giving two phases, i.e. the detergent-rich and the
detergent-depleted phases, the latter being collected. To optimize
fractionation between the glycans and the lipoglycans, the two phases
were both treated again twice. From SDS-PAGE analysis, using ManLAM and
LM standards, it was deduced that the parietal and cellular
mannoglycoconjugates which are soluble in the detergent-rich phase
correspond to a mixture of ManLAMs and LMs. The parietal and cellular
detergent-depleted phases were analyzed in the same way and from the
absence of migration on the gel, the compounds were assigned to
glycans. They were definitively identified, after Bio-Gel P-100 gel
filtration, by routine carbohydrate analysis (Ara/Man = 1.2 and
1.7 for the parietal and cellular glycans respectively) as AMs. Thus,
by means of the Triton X-114 method, the detergent-depleted phase was
found to contain AMs, while the detergent-rich phase included
lipoglycans identified as ManLAMs and LMs. To remove the LMs from the
ManLAMs, the corresponding cellular and parietal fractions were
purified by Bio-Gel P-100 gel filtration in the presence of sodium
deoxycholate buffer. Both fractions gave a similar chromatographic
profile (Fig. 2) characterized by two peaks, I and II. From SDS-PAGE analysis, peak I was assigned to the
ManLAMs, while peak II corresponded to LMs. Moreover, whatever their
parietal or cellular origin, ManLAMs and LMs showed the same
electrophoretic behavior on SDS-PAGE (Fig.
3). These assignments are in agreement
with routine carbohydrate analysis, which showed that parietal and
cellular ManLAMs contained, besides inositol, arabinose and mannose in
a ratio of 1.4 and 1.6, respectively. Likewise, mannose and inositol
were both found in the cellular and parietal LMs fractions.
Fig. 2.
Bio-Gel P-100 gel filtration chromatogram of
the fraction containing parietal ManLAMs and LMs. The fraction was
loaded on a Bio-Gel P-100 column (52 × 3 cm), eluted with 0.2 M NaCl, 0.25% sodium deoxycholate (w/v), 1 mM
EDTA, and 10 mM Tris, pH = 8, and monitored by
refractory index. Peaks I and II were assigned to
ManLAMs and LMs, respectively, from SDS-PAGE analysis. Cellular lipoglycans show the same chromatographic profile than the parietal ones.
[View Larger Version of this Image (8K GIF file)]
Fig. 3.
SDS-PAGE analysis of parietal and cellular
ManLAMs and related mannoconjugates from M. bovis BCG
Pasteur strain. 20 µg of parietal ManLAMs (lane a),
20 µg of parietal LMs (lane b), 20 µg of parietal ManAMs
(lane c), 200 µg of parietal ManAMs (lane d),
20 µg of cellular ManLAMs (lane e), 20 µg of cellular
LMs (lane f), 200 µg of cellular ManAMs (lane
g). The gel was colored with a silver stain containing periodic
acid.
[View Larger Version of this Image (79K GIF file)]
Purification scheme (Fig. 1) summarizes the amounts of ManLAMs, LMs,
and ManAMs2 of either
parietal or cellular origin recovered by our procedure. It can be
observed that the total amount of cellular material obtained (492 mg)
was much higher than for parietal material (93 mg). Moreover, it must
be underlined that the cellular ManLAMs were twice as abundant as the
cellular ManAMs, whereas the parietal ManLAMs were only half as
abundant as the parietal ManAMs.
Structural Features of Parietal and Cellular ManLAMs
As indicated in the literature, fatty acid residues (5, 8) and
mannooligosaccharide caps (9, 10) seem to be the key structural
features determining the ManLAM immunological activity. We therefore
investigated the presence and structure of the fatty acids and
mannooligosaccharide caps in parietal and cellular ManLAMs.
Mannooligosaccharide Caps
To characterize the expected
mannooligosaccharide caps, parietal and cellular ManLAMs were analyzed
by 1H-13C HMQC experiments (data not shown) as
described previously by Venisse et al. (11). The parietal
ManLAM C-1 resonances at
104.7 and
100.8 were respectively
assigned to 2-O-linked
-Manps and
t-
-Manps. Each of these resonances correlate with two
different proton resonances at
5.14,
5.12 and
5.06,
5.04, respectively, in agreement with the presence of
(1
2)-
-D-mannooligosaccharide caps. Likewise, these
mannooligosaccharide caps were found in the cellular ManLAMs. These cap
structures were also supported by the identification of
2-O-linked Manps from the alditol acetate analysis of the parietal and cellular ManLAMs (Table
I). From these data, the capping
percentage was determined from the (3,5-di-O-linked Araf
t-Araf) to (3,5-di-O-linked
Araf) ratio. It was found that the capping frequency of the
parietal ManLAMs (76%) was higher compared with that of the cellular
ManLAMs (48%). The structures of these mannooligosaccharide caps were
then investigated by capillary electrophoresis analysis. Both parietal
and cellular ManLAMs were submitted to mild acid hydrolysis, to APTS
tagging followed by reductive amination (21), and finally, the
oligosaccharides derivates were analyzed by capillary electrophoresis
monitored by laser-induced fluorescence. Fig.
4 represents the electrophoregram of the
APTS derivatives arising from the parietal ManLAMs showing eight peaks
assigned by coelectrophoresis using oligosaccharide-APTS standards and
by previous data on the parietal ManLAM mannooligosaccharide structures
(11). Peak I was assigned to free APTS reagent; peak II, which
corresponds to the major compound, was Ara-APTS; peak III, Man-APTS;
peak IV, mannoheptose-APTS reference; peak V, Araf-Ara-APTS; peak VI, Manp-Ara-APTS; peak VII,
Manp-Manp-Ara-APTS; and finally peak VIII,
Manp-Manp-Manp-Ara-APTS. The relative
quantitation of the different mannooligosaccharide caps was achieved by
peak integration (21). The major structural motif was the dimannosyl unit (78%), while mannosyl (15%) and trimannosyl (7%) were less frequent. Likewise, it was established that cellular ManLAMs contained the same mannooligosaccharide cap structures and in similar
amounts to parietal ManLAMs, i.e. 76, 17, and 7%,
respectively.
Table I.
Methylation analysis data of parietal and cellular ManLAMs from M. bovis BCG Pasteur strain
Molar ratio values are corrected by the use of effective
carbon-response factors (26).
|
|
Abbreviated name of the glycosyl residue |
Parietal
ManLAMs |
Cellular ManLAMs
|
|
|
|
mol % |
| Partially methylated alditols acetates
|
| 2,3,5-Tri-O-Me-1,4-di-O-Ac-arabinitol |
t-Araf |
2.3 |
5.6
|
| 3,5-Di-O-Me-1,2,4-tri-O-Ac-arabinitol |
2-O-Linked
Araf |
7.5 |
7.4
|
| 2,3-Di-O-Me-1,4,5-tri-O-Ac-arabinitol |
5-O-Linked
Araf |
38.3 |
35.6
|
| 2-O-Me-1,3,4,5-tetra-O-Ac-arabinitol |
3,5-Di-O-linked
Araf |
9.8 |
10.7
|
| 2,3,4,6-Tetra-O-Me-1,5-di-O-Ac-mannitol |
t-Manp |
23.4 |
17.7
|
| 3,4,6-Tri-O-Me-1,2,5-tri-O-Ac-mannitol |
2-O-Linked
Manp |
9.2 |
9.4
|
| 2,3,4-Tri-O-Me-1,5,6-tri-O-Ac-mannitol |
6-O-Linked
Manp |
2.7 |
5.3
|
| 3,4-Di-O-Me-1,2,5,6-tetra-O-Ac-mannitol |
2,6-Di-O-linked
Manp |
6.8 |
8.3 |
|
| Mancapping percentage
|
| a |
|
76 |
48 |
| b |
|
69 |
24 |
|
a
3,5-Di-O-linked Araf t-Araf to 3,5-di-O-linked Araf ratio.
|
b
2-O-Linked Araf t-Araf
to 2-O-linked Araf ratio.
|
|
Fig. 4.
Electrophoregram of oligosaccharides
derivatives obtained from the parietal ManLAMs after mild hydrolysis
(0.1 N HCl, 30 min at 110 °C) and derivatization with
APTS. 1.3 ng of oligosaccharide-APTS derivatives were loaded on a
470 mm × 50-µm capillary. Analysis was carried out at a
temperature of 20 °C with an applied voltage of 24 kV and monitored
by laser-induced fluorescence. Peak I, APTS; peak
II, Ara-APTS; peak III, Man-APTS; peak IV,
mannoheptose-APTS reference; peak V,
Araf-Ara-APTS; peak VI, Manp-Ara-APTS;
peak VII, Manp-Manp-Ara-APTS; peak VIII,
Manp-Manp-Manp-Ara-APTS.
[View Larger Version of this Image (11K GIF file)]
In summary, parietal and cellular ManLAMs share the same
mannooligosaccharide cap structure but differ in their capping
frequency, which was 76 and 48%, respectively.
Phosphatidyl-myo-inositol Anchor
Both parietal and cellular
ManLAMs were found to contain phosphorus and myo-inositol,
which are parts of the PI anchor. It was established by routine GC that
cellular ManLAMs contained 2.3 palmitic and 1.0 tuberculostearic
acids/phosphorus atom. Surprisingly, these fatty acids were not
observed in significant amounts in parietal ManLAMs. So, the PI anchor
structure of parietal ManLAMs was investigated by two-dimensional
heteronuclear NMR techniques.
The one-dimensional 31P spectrum of parietal ManLAMs showed
a single resonance at
0.066 ppm attributed to the phosphodiester from
the anchor (Fig. 5a). By means
of the 1H-31P HMQC and HMQC-HOHAHA experiments,
the proton resonances of the residues esterifying the phosphorus were
assigned. The 1H-31P HMQC spectrum (data not
shown) showed three direct correlations between phosphate and proton
resonances at
4.16, 3.99, and 3.93 tentatively assigned by analogy
to the literature data (15) to the H-1 of the myo-inositol
and H-3 and H-3
of the glycerol, respectively. The
myo-inositol was typified by the
1H-31P HMQC-HOHAHA spectrum (Fig.
6a) showing resonances at
4.34, 4.16, 3.87, 3.65, 3.61, and 3.40 respectively assigned to H-2, H-1, H-6, H-4, H-3, and H-5 of myo-inositol from the HOHAHA
experiments (data not shown) and literature data (15). The downfield
resonances of H-2 (
+0.11) and H-6 (
+0.13) are in
agreement with the expected anchor structure characterized by a
glycosylation of the myo-inositol at C-6 by the mannan core
and at C-2 by one Manp unit. From the
1H-31P HMQC-HOHAHA spectrum, it was deduced
that the remaining glycerol proton H-1, H-1
, and H-2 resonances
overlapped between
3.99 and
3.93, revealing that only the C-1
position is acylated thanks to the following literature data:
1,2-diacyl-3-phospho-sn-glycerol unit
(
H-1/H-1
4.25/4.03;
H-2 5.12) (27);
3-phosphoglycerol unit, (
H-1/H-1
3.68/3.61;
H-2 3.90) (28). Moreover, the H-1 and H-1
resonance
upfield shift (
= 0.26 to 0.1 ppm) is in agreement with the
absence of an acyl substituent on C-2. Thus, a lyso structure can be
proposed for the parietal ManLAM phosphatidyl moiety.
Fig. 5.
One-dimensional 31P NMR spectrum
(
31P:
4.00 to 4.00) of the parietal
(a) and cellular (b) ManLAMs from M. bovis BCG Pasteur strain. The spectra were recorded in
D2O at 313 K.
[View Larger Version of this Image (31K GIF file)]
Fig. 6.
Expanded region (
1H:
3.20-4.50; 31P:
0.20 to 0.15) of the
31P-decoupled, 1H-detected HMQC-HOHAHA spectrum
of the native (a) and deacylated (b) parietal
ManLAMs. Numerals correspond to the proton number of the
myo-inositol units and numerals with letter G, to
the proton number of the glycerol units.
[View Larger Version of this Image (26K GIF file)]
To support this lyso structure, the parietal ManLAMs were treated under
mild alkaline conditions followed by their analysis by one-dimensional
31P and two-dimensional 1H-31P HMQC
(not shown) and HMQC-HOHAHA experiments (Fig. 6b). As
expected, the glycerol H-3 and H-3
resonate at the same values as
those described for the native parietal ManLAMs, i.e.
3.99 and 3. 93. However, the H-1 and H-1
are shifted upfield to
3.71 and
3.68 (
= 0.25 ppm, approximately) in agreement with
the C-1 deacylation of the glycerol moiety. H-2 still overlaps with H-3 and H-3
precluding its precise localization, but confirming that this
position is not acylated. Taken together, these data demonstrate that
the parietal ManLAM PI anchor differs from the cellular one and from
those previously described in the literature by the absence of
C16 and C19 fatty acids and by the presence of
an unidentified acyl residue borne by the C-1 of the glycerol unit.
This two-dimensional 1H-31P NMR analytical
approach, which allowed the structural elucidation of the phosphate
substituents, could not be applied to the native cellular ManLAMs. In
contrast to the parietal ManLAMs, which showed a sharp peak in the
one-dimensional 31P spectrum (with a width of 9 Hz), the
cellular ManLAM spectrum exhibited a broad unresolved signal centered
at 0 ppm with a width of 150 Hz (Fig. 5b). In this case, no
connectivities between phosphate and protons were obtained in the
two-dimensional 1H-31P HMQC and HMQC-HOHAHA
experiments. This phenomenon was systematically observed when
phosphorus did not resonate as a well resolved sharp signal, indicating
a restricted mobility of the phosphate groups possibly due to
aggregation of the cellular ManLAMs as a consequence of their
amphipathic nature (29). Indeed, the deacylated cellular ManLAMs showed
a sharp phosphate resonance signal allowing the two-dimensional
1H-31P NMR approach to be applied. An expected
structure of the PI anchor was found, in which the
myo-inositol was esterified at C-1 by the phosphate and
glycosylated at C-2 by one
-D-Manp unit and
at C-6 by the mannan core. In conclusion, the NMR study indicates that
the parietal and cellular ManLAMs also differ through the lipid part of
the PI anchor.
To determine the structure of the acyl group borne by the glycerol
moiety of the parietal ManLAMs and also to define the PI anchor
structure of the cellular ManLAMs, a new analytical procedure was
developed. ManLAMs were submitted to acetolysis allowing cleavage between phosphate and glycerol, but preserving the acyl-glycerol residues (20). These residues, extracted by cyclohexane/water partition, were analyzed by GC/MS in EI and CI/NH3
ionization modes. The cellular ManLAMs EI-total ion current
chromatogram profile (Fig. 7a)
shows five peaks of interest. Four of them were assigned from the EI
and CI mass spectra analysis. Peak I is attributed either to 1- or
2-palmitoyldiacetyl-sn-glycerol from the CI spectrum dominated by the (M + NH4)+ ions at
m/z 432 and the EI fragment ions at m/z 354 (M-CH3COOH)+·; m/z 239 CH3-(CH2)14-C
O+ and
m/z 159 (M-CH3-(CH2)14-COO·)+.
Likewise peak II is assigned to either 1- or
2-tuberculostearoyldiacetyl-sn-glycerol. Finally, peaks IV
and V are assigned to
1,2-dipalmitoyl-3-acetyl-sn-glycerol and
1-tuberculostearoyl-2-palmitoyl-3-acetyl-sn-glycerol,
respectively. In the last compound, the palmitoyl residue was
unequivocally localized at the C-2 position from the reporter ion
m/z 341 arising from the fragmentation of the molecular ions
between C-1 and C-2 of glycerol resulting in charged fragments having
lost the primary ester group together with C-1 (30). These data reveal
the heterogeneity of the phosphatidyl moiety, since at least four
molecular species were identified that differ in C16 and
C19 fatty acid composition and location. From the
integration of the total ion current chromatogram peaks, corrected by a
response factor, compound V is the major component (53%), while
compound II is the least abundant (5%). Finally, compounds I and IV
represent 22 and 19, respectively. Due to its low abundance (1%),
compound III could not be identified.
Fig. 7.
GC/MS chromatogram profile in EI mode of the
acetolysis subproducts from cellular (a) and parietal
(b) ManLAMs. Peak I was assigned to
1-palmitoyl-2,3-diacetyl-sn-glycerol or to
1,3-diacetyl-2-palmitoyl-sn-glycerol according to following
ions, in CI mode m/z 432 (M + NH4)+,
in EI mode m/z 354 (M-CH3COOH)+·, 239 (C15H31CO)+, 159 (M-C15H31COO·)+. Likewise,
peak II was assigned to
1-tuberculostearoyl-2,3-diacetyl-sn-glycerol or to
1,3-diacetyl-2-tuberculostearoyl-sn-glycerol according to m/z 474 (M + NH4)+ in CI mode,
m/z 396 (M-CH3COOH)+·, 281 (C18H37CO)+, 159 (M-C18H37COO·)+ in EI mode.
Peak IV was assigned to
1,2-dipalmitoyl-3-acetyl-sn-glycerol, m/z 628 (M + NH4)+ in CI mode, m/z 550 (M-CH3COOH)+·, 355 (M-C15H31COO·)+, 341 (M-·CH2OCOC15H31)+,
313 (M-C15H31COO·-CH2CO)+,
239 (C15H31CO)+ in EI mode.
Peak V was assigned to
1-tuberculostearoyl-2-palmitoyl-3-acetyl-sn-glycerol, m/z 670 (M + NH4)+ in CI mode,
m/z 592 (M-CH3COOH)+·, 397 (M-C15H31COO·)+, 355 (M-C18H37COO·)+, and
(M-C15H31COO·-CH2CO)+,
341 (M-·CH2OCOC18H37)+,
313 (M-C18H37COO·-CH2CO)+,
281 (C18H37CO)+, 239 (C15H31CO)+ in EI mode.
c, EI spectrum of compound III; d,
CI/NH3 spectrum of compound III. Unnumbered peaks (in
a) correspond to contaminants. Ac,
C16, and C19 represent
acetyl, palmitoyl, and tuberculostearoyl residues esterifying
glycerol.
[View Larger Version of this Image (21K GIF file)]
The parietal ManLAM EI-total ion current chromatogram profile (Fig.
7b) shows only one peak with a retention time corresponding to the unidentified compound III from the cellular ManLAMs. The EI
spectrum (Fig. 7c) is dominated by the fragment ions at
m/z 159 typifying a lyso-glycerol and, in the high mass
range, by the peak at m/z 544 tentatively assigned to the
molecular ions. Indeed, the CI/NH3 spectrum (Fig.
7d) shows one peak located at the expected value of
m/z 562 (M + NH4)+ confirming the
molecular weight of 544 Da. From this latter value, a molecular weight
of 386 Da was deduced for the fatty acid, suggesting the presence of
two oxygen atoms tentatively assigned to two hydroxyl groups. This
hypothesis is supported by the fact that these fatty acids were not
detected by routine GC analysis. Therefore, the fatty acids released by
alkaline hydrolysis of parietal ManLAMs were derivatized as methyl
esters, peracetylated, and analyzed by GC and GC/MS in EI and
CI/NH3 ionization modes. The GC chromatogram (not shown) is
dominated by one peak attributed to a fatty acid methyl ester of 356 Da
molecular mass, containing one acetyl group instead of two as
previously expected, consistent with a monohydroxyl stearic acid.
However, the molecular mass of the acetylated fatty acid (342 Da) is 44 mass units lower than the one expected. To support this conclusion and
to localize the hydroxyl function, the fatty acid methyl esters
obtained from parietal ManLAMs were trimethylsilylated and analyzed by
GC/MS. The chromatogram (Fig. 8a) is dominated by one peak
(peak 4) assigned to a TMS fatty acid methyl ester of 386 Da
molecular mass (Fig. 8b). This is in agreement with the mass
difference of 30 Da between a TMS and an acetyl residue and confirms a
monohydroxyl stearic acid structure. Moreover, from the reporter
EI-fragment ions at m/z 187 and 301 (Fig. 8c),
this hydroxyl group was unambiguously localized at C-12.
Fig. 8.
a, flame ionization detector gas
chromatogram profile of the trimethylsilylated fatty acid methyl esters
from parietal ManLAMs. Peak 1, C15 methyl ester
reference; peak 2, C16 methyl ester; peak
3, C18 methyl ester; peak 4,
12-O-TMS-12-hydroxystearic acid methyl ester assigned
according the following ions, in CI/NH3 mode (b)
m/z 387 (M + H)+, 404 (M + NH4)+, in EI mode (c) m/z
187 (CH3(CH2)5CH = O+Si(CH3)3), 301 ((CH3)3SiO+ = CH(CH2)10CO2CH3);
peak 5, 12-O-TMS-12-hydroxytuberculostearic acid
methyl ester assigned according the following ions, in CI mode
m/z 401 (M + H)+, 418 (M + NH4)+, in EI mode m/z 187 and 315 and the reporting ions at m/z 149 and 167 typifying a
C-methyl ramification located at position 10 (31).
[View Larger Version of this Image (16K GIF file)]
In summary, TMS and peracetylation analysis converge to a
12-hydroxystearic acid structure, but with a molecular mass of 300 Da,
which is 86 Da lower than that deduced from the acetolysis-GC/MS experiments. Thus, it is tempting to conclude that the hydroxyl function in the native parietal ManLAMs was not free, but rather esterified by a methoxypropanoic residue. Besides this major fatty acid
(Fig. 8a), palmitic acid, stearic acid, and a
12-hydroxytuberculostearic acid were found in small amounts as their
methyl ester derivatives: peaks 2, 3, and 5,
respectively.
Secretion of IL-8 and TNF-
by Human DCs in Response to Parietal
and Cellular ManLAMs
To investigate the consequences of the structural differences
established between parietal and cellular ManLAMs on their
immunological activity, we compared the ability of parietal and
cellular ManLAMs to stimulate cytokine release from human DCs. DCs are
the most professional antigen-presenting cells specifically adapted to initiate T cell responses. In addition to this function, DCs are capable of producing a number of cytokines, including chemokines that
recruit other leukocytes to the sites of antigen contact. It is now
well established that DCs differentiate from human monocytes in the
presence of IL-4 and GM-CSF (32). Using this system, we have shown
previously that BCG is a potent stimulus for DCs (25). BCG induces a
maturational step in DCs that is accompanied by the up-regulation of
surface markers such as CD83 and CD86 and by the down-regulation of the
endocytic activity. In addition, BCG induces the release of TNF-
and
IL-83 from DCs.
In the present work we compared the ability of parietal and cellular
ManLAMs to stimulate the production of IL-8 in DCs. Fig. 9a demonstrates that parietal
ManLAMs induce IL-8 secretion in a dose-dependent manner.
Unstimulated DCs produced low basal levels of IL-8 ranging from 50 to
150 pg/ml/105 cells. Parietal ManLAMs at a dose of 10 µg/ml stimulated IL-8 release more than 25-fold. In contrast,
cellular ManLAMs exhibited significantly less stimulatory activity. The
IL-8 stimulatory activity was completely abolished after removal of the
fatty acid residues by mild alkaline treatment. Moreover, ManAMs that
lack the PI anchor failed to release significant amounts of IL-8 when used at the same concentration (data not shown).
Fig. 9.
IL-8 (a) and TNF-
(b) release by human dendritic cells stimulated by parietal
ManLAMs (
), cellular ManLAMs (
), and deacylated cellular ManLAMs
(
).
[View Larger Version of this Image (13K GIF file)]
Previous works have shown that ManLAMs from M. tuberculosis
Erdman are poor inducers of TNF-
release from the THP-1 monocytic cell line compared with the PI-GAMs from M. smegmatis, which
correspond to the parietal LAMs (5, 7). We therefore investigated the effect of the two types of ManLAMs on TNF-
production by DCs. Parietal ManLAMs at 10 µg/ml induced the secretion of more than 300 pg/ml TNF-
, while cellular ManLAMs at the same concentration almost
failed to elicit TNF-
secretion (Fig. 9b). This finding is consistent with a previous report demonstrating that cellular ManLAMs were unable to induce TNF-
from THP-1 cells (7).
DISCUSSION
LAMs are important mycobacterial antigens that can be recognized
by T cells in the context of CD1 molecules. However, CD1-restricted T
cell lines were shown to discriminate between ManLAMs derived from
M. leprae and M. tuberculosis, suggesting subtle
but significant structural differences which can, up to date, only be
explained by differences in the mannooligosaccharide cap frequency
(10). This assumption was also recently advanced by Schlesinger
et al. (33) to explain differences in the ability of ManLAMs
from Erdman and H37Ra to serve as ligands for the macrophage mannose
receptors. In addition, LAMs can stimulate the production of cytokines
such as TNF-
in monocytes/macrophages, thereby contributing to the clearance of mycobacteria. Conversely, it has been suggested that the
poor cytokine stimulatory activity of LAMs from virulent mycobacteria is responsible for the intramacrophagic persistence of the mycobacteria (5). However, the molecular basis underlying these differences in the
immunological activity of LAMs are poorly understood. Thus, despite
continuing efforts of Brennan's and Puzo's groups to establish detailed structures of ManLAMs based on the use of sophisticated analytical tools such as two-dimensional NMR spectroscopy and matrix-assisted laser desorption/ionization mass spectrometry, the
above mentioned immunological LAM properties suggest that the present
structural models are incomplete. This paradoxical situation can be
explained by the structural complexity of the ManLAMs, but also and
essentially by the molecular heterogeneity of the ManLAM fractions
analyzed. So, it appears clearly that the obtention of homogenous
ManLAM fractions remains a key step in the understanding, at the
molecular level, of the ManLAM properties. Analyses of ManLAMs by
matrix-assisted laser desorption/ionization mass spectrometry revealed
substantial molecular weight heterogeneity estimated to be 6 kDa and
attributed to differences in the degree of glycosylation of the mannan
core and the arabinan domain. More detailed structural studies of the
parietal ManLAMs from M. bovis BCG revealed two equally
frequent types of mannan core, which differ at their reducing end by
the presence or absence of the phosphatidyl-myo-inositol
anchor, but also by the t-Manp-(
1
2)-Manp branching frequency, suggesting that the parietal ManLAM preparation was contaminated by ManAMs (15).
In this report, we present a new extraction and purification
protocol for ManLAMs from BCG. According to its extraction mode two
types of ManLAMs were distinguished and designated as parietal and
cellular (16). The parietal ManLAMs were obtained, as described by
Venisse et al. (11), from extraction of delipidated cells by
an ethanol/water mixture, while the cellular ManLAMs were obtained from
the resulting cells disrupted and extracted as mentioned above. The
second major feature of this new protocol was the fractionation of the
ManAMs and ManLAMs using the Triton X-114 phase separation method. This
approach was previously applied to completely resolve membranous
lipopolysaccharides and membranous proteins of M. leprae (34) or to remove LPS from exopolysaccharides (35). ManLAMs are
amphipathic molecules that aggregate with ManAMs, hindering their
separation either by anion exchange or gel filtration chromatography. Triton X-114 improves the dissociation of amphipathic and hydrophilic molecules and, at temperatures beyond the cloud point (22 °C), the
detergent-rich phase was found, by SDS-PAGE, to contain the ManLAMs,
while the ManAMs were present in the detergent-depleted phase. Thus,
the Triton X-114 partitioning method appears to be a powerful approach
to efficiently remove ManAMs from the ManLAMs. So, ManLAMs devoid of
ManAMs were obtained and two types of ManLAMs, called parietal and
cellular, were structurally defined for M. bovis BCG.
Quantitative analysis of the individual fractions revealed that
parietal mannoconjugates were less abundant than cellular ones, 16 and
84%, respectively, and that the proportion of cellular ManLAMs was 10 times higher than the parietal ManLAMs.
The comparative structural analysis of the two ManLAMs revealed subtle
structural differences between the parietal and cellular ManLAMs (Fig.
10), supporting the pertinence of the
extraction and purification strategy. Structural differences include
the percentage of the mannooligosaccharide caps and the PI anchor lipid
moiety. Capping is more frequent in the parietal ManLAMs (76%) as
compared with cellular ones (48%). These values were determined from
the (3,5-di-O-linked Araf
t-Araf)
to 3,5-di-O-linked Araf unit ratio established
routinely from the alditol acetates analysis. Alternatively, it can
also be calculated from the (t-Manp
2,6-di-O-linked Manp) to
3,5-di-O-linked Araf ratio, but in this case the
percentage of t-Manp caps is higher (16.6%) than the
percentage of 3,5-di-O-linked Araf (9.8%). This
observation can be explained by the low amount of
di-O-linked Manp compared with t-Manp
released during hydrolysis of the ManLAMs (36). Another method has been
used as the (2-Araf
t-Araf) to
2-Araf ratio (36), leading to capping frequencies of 69 and
24% for the parietal and cellular ManLAMs, respectively (Table I).
However this approach may be less accurate, since it is based on the
assumption that each arabinan side chain contains only one
2-O-linked Araf unit. Nevertheless, whatever the
method applied, the capping of parietal ManLAMs is more frequent than
capping of cellular ManLAMs. The ManLAM mannooligosaccharide cap
structures were previously described as single
-Manp,
Manp-(1
2)-Manp and
Manp-(1
2)-Manp-(1
2)-Manp using LC/MS (11). A new analytical approach, based on mild hydrolysis of ManLAMs, tagging by APTS followed by capillary electrophoresis analysis monitored by laser-induced fluorescence, was applied to both
parietal and cellular ManLAMs. The same three structures of
mannooligosaccharide caps were evidenced with the same relative abundance for both parietal and cellular ManLAMs:
-Manp
(16 ± 1%), Manp-(1
2)-Manp (77 ± 1%), and
Manp-(1
2)-Manp-(1
2)-Manp (7 ± 1%). Relative quantification was achieved by peak
integration. The analysis was performed in the microgram range of
ManLAMs, demonstrating the sensitivity of this method.
Fig. 10.
Partial structural models proposed for the
parietal (a) and the cellular (b) ManLAMs from
M. bovis BCG Pasteur strain.
,
12-O-(methoxypropanoyl)-12-hydroxystearic acid;
,
represents at 53% C19, C16; at 22% OH,
C16; at 19% C16, C16; at 5% OH,
C19; at 1% OH,
12-O-(methoxypropanoyl)-12-hydroxystearic acid; , fatty acid or not;
, t-
-Araf; Cap corresponds to
77% dimannosyl unit, 16% mannosyl unit, and 7% trimannosyl unit. The
percentage of capping is 76 and 48% for the parietal and cellular
ManLAMs, respectively.
[View Larger Version of this Image (11K GIF file)]
The other unexpected difference between parietal and cellular ManLAMs
concerned the lipid part of the ManLAM PI anchors. The cellular ManLAM
anchors were mainly found to contain 1- or
2-palmitoyl-sn-glycerol (22%), 1- or
2-tuberculostearoyl-sn-glycerol (5%),
1,2-dipalmitoyl-sn-glycerol (19%), and
1-tuberculostearoyl-2-palmitoyl-sn-glycerol (53%). In
contrast, the parietal ManLAM PI anchor was found to be composed of a
single type of acylglycerol identified as the unusual
1-[12-O-(methoxypropanoyl)-12-hydroxystearoyl]-sn-glycerol.
Finally, we were interested in the biological effects of these
structurally different ManLAMs from BCG. Both parietal and cellular
ManLAMs of BCG induced expression of IL-8 and TNF-
from human DCs.
However, parietal ManLAMs turned out to be better stimulators of IL-8
production in DCs compared with cellular ManLAMs. It was previously
reported that H37Ra and its LAMs were able to stimulate the release of
IL-8 from human alveolar macrophages, although the identification of
the mycobacterial species remains suspicious (37). In addition, we
found that only parietal ManLAMs stimulated TNF-
secretion from DCs.
This last point is consistent with our earlier finding that cellular
ManLAMs are unable to stimulate TNF-
secretion from THP-1 cells (7).
It thus appears that structural modifications of ManLAMs are able to
regulate expression of the cytokines involved in macrophage and
dendritic cell activation. Structural differences between cellular and
parietal ManLAMs affect the percentage of mannooligosaccharide caps and
the lipid part of the PI anchor. The fact that the ManLAM activities
are abrogated after deacylation and the observation that ManAMs, which
lack the PI anchor, are unable to stimulate cytokine production are consistent with the assumption that the PI anchor lipid part is an
essential element for the immunological activities of the ManLAMs.
The parietal ManLAM PI anchor lipid part is characterized by the
presence of a unique fatty acid, found for the first time in the
mycobacteria genus and identified as
12-O-(methoxypropanoyl)-12-hydroxystearic acid. Moreover,
this fatty acid was found to exclusively acylate the glycerol at C-1
leading to a lyso form. Therefore, it is intriguing to speculate that
this acylglycerol modification could regulate cytokine secretion and
consequently modulate intracellular survival of mycobacteria. Indeed,
it was recently established that LPS from Salmonella
typhimurium, modified by the addition of a hydroxymyristate in the
lipid A part, altered TNF-
expression by adherent cells (38). More
excitingly, it was found that these modifications were under the
control of virulence genes (phoP-phoQ). It can be
advanced that mycobacteria can escape from intramacrophagic destruction by adapting their ManLAM PI anchor structures to prevent stimulation of cytokine synthesis. Further structural definition of
anchors from pathogenic mycobacteria species will help to clarify their
role in mycobacterial virulence. As reported previously, ManLAMs are
also ligands of the mannose receptor expressed on macrophages and DCs.
ManLAMs thus favor mycobacterial adhesion. Concomitantly, however,
ManLAMs internalized via mannose-receptor-mediated endocytosis can be
presented in the context of CD1 and stimulate antimycobacterial T cell
responses. It should also be considered that structural differences may
affect uptake, intracellular handling, and cell surface presentation of
individual ManLAM molecules. Besides the PI anchor, it was found that
the mannooligosaccharide caps play a key role in the adhesion to
macrophages and the subsequent induction of T-lymphocyte responses,
suggesting that the molecular basis of ManLAM functional diversity is
not yet precisely understood.
To further clarify these molecular mechanisms of recognition, it will
be important, in future studies, to establish detailed structures of
parietal and cellular ManLAMs from virulent and pathogenic
mycobacterial strains and to compare their activities in biological
processes such as cell adhesion, antigen presentation, cytokine
stimulation, and T cell activation.
FOOTNOTES
*
This work was supported by grants from the Région
Midi-Pyrénées (RECH/9307911), from the Mission Scientifique
et Technique du Ministère de l'Education Nationale, de
l'Enseignement Supérieur et de la Recherche (ACC SV6 9506005),
and from the Austrian Science Foundation (to M. T.) (P11758-Med).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
33-5-61-33-59-10; Fax: 33-5-61-33-59-12; E-mail:
germain{at}ipbs.fr.
1
The abbreviations used are: BCG, bacillus
Calmette Guérin; AMs, arabinomannans; APTS,
1-aminopyrene-3,6,8-trisulfonate; CI, chemical ionization;
C15, pentadecanoic acid; C16, palmitic acid; C18, stearic acid; C19, tuberculostearic acid;
DCs, dendritic cells; LAMs, lipoarabinomannans; ManLAMs, LAMs with
mannosyl extensions; dManLAMs, deacylated ManLAMs; EI, electron impact;
GC, gas chromatography; GC/MS, gas chromatography coupled to mass
spectrometry; GM-CSF, granulocytes/macrophages-colony stimulating
factor; HMQC, heteronuclear multiple quantum correlation spectroscopy;
HOHAHA, homonuclear Hartmann-Hahn spectroscopy; IL, interleukin;
ManAMs, arabinomannans with mannosyl extensions; LMs, lipomannans; PI
anchor, phosphatidyl-myo-inositol anchor; PI-GAMs,
phosphoinositol-glyceroarabinomannans; PAGE, polyacrylamide gel
electrophoresis; TMS, trimethylsilyl; TNF, tumor necrosis factor.
2
Parietal and cellular AMs were identified as
ManAMs, i.e. with mannosyl extensions on the arabinan side
chains (J. Nigou, M. Gilleron, and G. Puzo, unpublished
observation).
3
M. Thurnher, unpublished data.
ACKNOWLEDGEMENTS
We gratefully acknowledge Dr. Alain
Vercellone and Dr. Olivier Adam for stimulating discussions and Therese
Brando and Christine Papesh for technical assistance.
REFERENCES
-
Bloom, B. R., and Murray, G. J.
(1992)
Science
257,
1055-1064
[Abstract/Free Full Text]
-
Fine, P. E. M.
(1989)
Rev. Infect. Dis.
11,
S353-S359
-
Roche, P. W., Triccas, J. A., and Winter, N.
(1995)
Trends Microbiol.
3,
397-401
[CrossRef][Medline]
[Order article via Infotrieve]
-
Britton, W. J., Roche, P. W., and Winter, N.
(1994)
Trends Microbiol.
2,
284-288
[CrossRef][Medline]
[Order article via Infotrieve]
-
Roach, T. I. A., Barton, C. H., Chatterjee, D., and Blackwell, J. M.
(1993)
J. Immunol.
150,
1886-1896
[Abstract]
-
Chan, J., Fan, X., Hunter, S. W., Brennan, P. J., and Bloom, B. R.
(1991)
Infect. Immun.
59,
1755-1761
[Abstract/Free Full Text]
-
Gilleron, M., Himoudi, N., Adam, O., Constant, P., Venisse, A., Rivière, M., and Puzo, G.
(1997)
J. Biol. Chem.
272,
117-124
[Abstract/Free Full Text]
-
Venisse, A., Fournié, J. J., and Puzo, G.
(1995)
Eur. J. Biochem.
231,
440-447
[Medline]
[Order article via Infotrieve]
-
Schlesinger, L. S., Hull, S. R., and Kaufmann, T. M.
(1994)
J. Immunol.
152,
4070-4079
[Abstract]
-
Sieling, P. A., Chatterjee, D., Porcelli, S. A., Prigozy, T. I., Mazzaccaro, R. J., Soriano, T., Bloom, B. R., Brenner, M. B., Kronenberg, M., Brenan, P. J., and Modlin, R. L.
(1995)
Science
269,
227-230
[Abstract/Free Full Text]
-
Venisse, A., Berjeaud, J.-M., Chaurand, P., Gilleron, M., and Puzo, G.
(1993)
J. Biol. Chem.
268,
12401-12411
[Abstract/Free Full Text]
-
Hunter, S. W., and Brennan, P. J.
(1990)
J. Biol. Chem.
265,
9272-9279
[Abstract/Free Full Text]
-
Chatterjee, D., Lowell, K., Rivoire, B., McNeil, M., and Brennan, P. J.
(1992)
J. Biol. Chem.
267,
6234-6239
[Abstract/Free Full Text]
-
Brennan, P. J., and Nikaido, H.
(1995)
Annu. Rev. Biochem.
64,
29-63
[CrossRef][Medline]
[Order article via Infotrieve]
-
Venisse, A., Rivière, M., Vercauteren, J., and Puzo, G.
(1995)
J. Biol. Chem.
270,
15012-15021
[Abstract/Free Full Text]
-
Delmas, C., Gilleron, M., Brando, T., Vercellone, A., Gheorgiu, M.,
Rivière, M., and Puzo, G. (1997) Glycobiology 7, in press
-
Bordier, C.
(1981)
J. Biol. Chem.
256,
1604-1607
[Abstract/Free Full Text]
-
Ciucanu, I., and Kerek, F.
(1984)
Carbohydr. Res.
131,
209-217
[CrossRef]
-
Schnitger, H., Papenberg, K., Ganse, E., Czok, R., Bücher, T., and Adam, H.
(1959)
Biochem. Z.
332,
167-185
[Medline]
[Order article via Infotrieve]
-
Ferguson, M. A. J., Haldar, K., and Cross, G. A. M.
(1985)
J. Biol. Chem.
260,
4963-4968
[Abstract/Free Full Text]
-
Guttman, A., Chen, F. T. A., Evangelista, R. A., and Cooke, N.
(1996)
Anal. Biochem.
233,
234-242
[CrossRef][Medline]
[Order article via Infotrieve]
-
Lerner, L., and Bax, A.
(1986)
J. Magn. Res.
69,
375-380
-
Shaka, A. J., Barker, P. B., and Freeman, R.
(1985)
J. Magn. Res.
64,
547-552
-
Marion, D., and Wüthrich, K.
(1983)
Biochem. Biophys. Res. Commun.
113,
967-974
[CrossRef][Medline]
[Order article via Infotrieve]
-
Thurnher, M., Ramoner, R., Gastl, G., Radmayr, C., Böck, G., Herold, M., Klocker, H., and Bartsch, G.
(1997)
Int. J. Cancer
70,
128-134
[CrossRef][Medline]
[Order article via Infotrieve]
-
Sweet, D. P., Shapiro, R. H., and Albersheim, P.
(1975)
Carbohydr. Res.
40,
967-974
-
Wang, Y., and Hollingsworth, R. I.
(1995)
Anal. Biochem.
225,
242-251
[CrossRef][Medline]
[Order article via Infotrieve]
-
Glushka, J., Cassels, F. J., Carlson, R. W., and Van Halbeek, H.
(1992)
Biochemistry
31,
10741-10746
[CrossRef][Medline]
[Order article via Infotrieve]
-
Mühlradt, P. F., Wray, V., and Lehmann, V.
(1977)
Eur. J. Biochem.
81,
193-203
[CrossRef][Medline]
[Order article via Infotrieve]
-
Budzikiewicz, H., and Rullkötter, J.
(1973)
Z. Naturforsch.
28c,
499-504
-
Leopold, K., and Fischer, W.
(1993)
Anal. Biochem.
208,
57-64
[CrossRef][Medline]
[Order article via Infotrieve]
-
Cella, M., Sallusto, F., and Lanzavecchia, A.
(1997)
Curr. Opin. Immunol.
9,
10-16
[CrossRef][Medline]
[Order article via Infotrieve]
-
Schlesinger, L. S., Kaufmann, T. M., Iyer, S., Hull, S. R., and Marchiando, L. K.
(1996)
J. Immunol.
157,
4568-4575
[Abstract]
-
Hunter, S. W., Rivoire, B., Mehra, V., Bloom, B. R., and Brennan, P. J.
(1990)
J. Biol. Chem.
265,
14065-14068
[Abstract/Free Full Text]
-
Adam, O., Vercellone, A., Paul, F., Monsan, P. F., and Puzo, G.
(1995)
Anal. Biochem.
225,
321-327